CMOTEC_B: Q2 2024 saw record sales, narrowed losses, and a successful rights issue boosting liquidity

About this update from Scandinavian Chemotech Ab Class B

Record sales in Q2 2024 driven by Animal Care, improved losses, and successful rights issue raised 9.73 MSEK. Registration in India and further financing remain key for future growth.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Scandinavian Chemotech Ab Class B